Business Parks & Science Centres



Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 600x60px
Document › Details

Orexo AB. (8/26/10). "Press Release: Orexo Notes Significant Change in Its Owner Structure". Uppsala.

Organisations Organisation Orexo AB (OMX Nordic List, Mid Cap: ORX)
  Group Orexo (Group)
  Organisation 2 Novo A/S
  Group Novo Group (Group)
Products Product Abstral®
  Product 2 anti-inflammatory drug
Index term Index term Orexo–Novo Group: investment, 201008 acquisition additional 1.4m shares=6% raising share to 16.7% or 24.2% incl convertible bonds for Novo A/S
Persons Person Bjerke, Torbjörn (Karolinska Institutet 201306 CEO of Karolinska Development before Orexo CEO before Biolipox CEO)
  Person 2 Wright, Robin (Orexo 201008 CFO)

Orexo AB (STO: ORX) notes today that its shareholder Novo A/S has increased its ownership position in Orexo by acquiring an additional 1,397,142 shares representing approximately 6.0% of the current outstanding shares of the company. Upon the closing of the transaction, Novo A/S will own 3,893,184 shares, or approximately 16.7% of Orexo. Furthermore, Novo A/S holds an Orexo convertible bond, which if converted would represent an additional 2,340,000 shares equal to approximately 9.1% of the company after conversion, giving Novo A/S a 24.2% share of the total ownership on an as-converted basis.

For further information, contact:
Torbjörn Bjerke, President and CEO
Tel: +46 (0) 708-661990

Robin Wright, EVP and CFO
Tel: +44 7720 300025

About Orexo

Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. Based on Orexo's well established and proven reformulation technologies, Orexo will develop proprietary products targeted at the Specialty Pharmaceutical market and intend to commercialise the products itself in major markets. The project development builds on Orexo's core competences in R&D, which have previously resulted in several successful products, currently out-licensed through worldwide partnership agreements to larger pharmaceutical companies. Orexo has today four products on the market of which AbstralTM for the treatment of breakthrough pain in cancer patients is launched in most of Europe. Orexo has its head office located in Uppsala, Sweden. More information can be found at

This is information that Orexo AB (publ.) is required to disclose pursuant to the Swedish Securities Markets Act. The information was provided for public release on August 26, 2010 at 17:30 CET.

Record changed: 2015-08-10


Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 600x60px

More documents for Orexo (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Sacura GmbH CRO BIO-Europe Spring 2017 600x60px wpexp

» top


Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture Sacura e.tract software BIO-Europe Spring 2017 Barcelona 120x240px wps2 Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture [LSE] – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px